PT - JOURNAL ARTICLE AU - S C Buttery AU - A Lewis AU - L Latimer AU - S V Kemp AU - P L Shah AU - D Waller AU - K Lau AU - S Jordan AU - N J Greening AU - S Rathinam AU - W Banya AU - J Moxham AU - A J B Kirk AU - R Bilancia AU - S Tenconi AU - K Housley AU - R Lawson AU - M C Steiner AU - N S Hopkinson TI - Comparative Effect of Lung volume reduction surgery for Emphysema and Bronchoscopic lung volume reduction with valve placement: the CELEB trial AID - 10.1183/13993003.congress-2022.4567 DP - 2022 Sep 04 TA - European Respiratory Journal PG - 4567 VI - 60 IP - suppl 66 4099 - http://erj.ersjournals.com/content/60/suppl_66/4567.short 4100 - http://erj.ersjournals.com/content/60/suppl_66/4567.full SO - Eur Respir J2022 Sep 04; 60 AB - Introduction: Lung volume reduction surgery (LVRS) and bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBVs) improve lung function, exercise capacity and quality of life in appropriately selected patients with emphysema. However, there are no direct comparison data to aid decision-making in people who are suitable for both.Aims and objectives: We sought to investigate if LVRS is superior to BLVR over 12 months.Methods: The CELEB study was a randomised controlled single-blind superiority trial, comparing LVRS outcomes at 1 year with BLVR, assessed using the iBODE score, a composite disease severity measure, which includes body mass index, airflow obstruction, dyspnoea, and exercise capacity (incremental shuttle walk test).Results: Eighty-eight patients (48% female, mean(±SD) age 64.6±7.7, FEV1%predicted 31.0±7.9) were randomised to either LVRS (n=41) or BLVR (n=47). At 12 months follow up, both groups improved to a similar extent, with neither the improvement in the i-BODE composite score (LVRS: -1.10 (1.44), BLVR: -0.82 (1.61) p=0.54) nor any of its individual components differing between the two treatment groups. Both treatments produced similar reductions in gas trapping; RV% predicted (LVRS -36.1 (-54.1, -10), BLVR: -30.5 (-59.0, -9) p=0.91). Survival did not differ between treatment groups, with one death in each arm, over the 12 months (EBV: 3 months, LVRS: 6 months).Conclusion: In patients who are considered to be suitable for both treatments, we found no evidence that outcomes following LVRS were superior to BLVR.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 4567.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).